תמיסה איזוטונית של סולפט הגנטמיצין להזרקה 80 מ"ג/100 מ"ל ישראל - עברית - Ministry of Health

תמיסה איזוטונית של סולפט הגנטמיצין להזרקה 80 מ"ג/100 מ"ל

teva medical marketing ltd. - gentamicin as sulfate 80 mg / 100 ml - solution for injection - gentamicin - treatment of serious infections caused by susceptible microorganisms.

גאמאגארד S/D אימונוגלובולין תוך ורידי 2.5 גר' ישראל - עברית - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 2.5 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

גאמאגארד S/D אימונוגלובולין תוך ורידי 5 גר' ישראל - עברית - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 5 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

גאמאגארד S/D אימונוגלובולין תוך ורידי 10 גר' ישראל - עברית - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 10 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

פלזמהלייט "א" תמיסה להזרקה 7.4 PH ישראל - עברית - Ministry of Health

פלזמהלייט "א" תמיסה להזרקה 7.4 ph

teva medical marketing ltd. - magnesium chloride 0.3 mg/ml; potassium chloride 0.37 mg/ml - solution for injection - solutions affecting the electrolyte balance - indicated as a source of water and electrolytes or as an alkalinizing agent.

דקסטרוז %5 ו-%0.9 סודיום כלוריד להזרקה USP ישראל - עברית - Ministry of Health

דקסטרוז %5 ו-%0.9 סודיום כלוריד להזרקה usp

teva medical marketing ltd. - glucose hydrous 50 mg/ml; sodium chloride 9 mg/ml - solution for infusion - solutions for parenteral nutrition - source of water, electrolytes and calories.

Intravenous devices ישראל - עברית - Ministry of Health

intravenous devices

טבע מדיקל (שיווק) בע"מ - אחות - מתן עירויים דרך הוריד באופן נשלט ומבוקר

Intravenous devices ישראל - עברית - Ministry of Health

intravenous devices

טבע מדיקל (שיווק) בע"מ - אחות - מתן עירויים דרך הוריד באופן נשלט ומבוקר

קלינולאיק 20% ישראל - עברית - Ministry of Health

קלינולאיק 20%

remedix care ltd - olive oil; soya oil - תחליב לאינפוזיה - olive oil 80 %; soya oil 20 % - oil - oil - source of lipids during parenteral nutrition in situations where oral or enteral feeding is impossible, insufficient or contra-indicated.

רקומבינאט IU 250 ישראל - עברית - Ministry of Health

רקומבינאט iu 250

teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.